Mark Freedman
Affiliations: | Immunology | University of Ottawa, Ottawa, ON, Canada |
Google:
"Mark Freedman"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Jack P. Antel | research scientist | University of Ottawa (Cell Biology Tree) |
Children
Sign in to add trainee| Robert A. Pon | grad student | 2001 | University of Ottawa |
| Zhihong Chen | grad student | 2003-2009 | University of Ottawa |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jiang T, Shanmugasundaram M, Božin I, et al. (2024) Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons. Journal of Comparative Effectiveness Research. e230161 |
| Wurtz LI, Knyazhanskaya E, Sohaei D, et al. (2024) Identification of brain-enriched proteins in CSF as biomarkers of relapsing remitting multiple sclerosis. Clinical Proteomics. 21: 42 |
| Hartung HP, Berger T, Bermel RA, et al. (2024) ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial. Journal of Neurology |
| Kalincik T, Sharmin S, Roos I, et al. (2024) Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry |
| Freedman MS, Gnanapavan S, Booth RA, et al. (2024) Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. Ebiomedicine. 101: 104970 |
| Freedman MS, Coyle PK, Hellwig K, et al. (2024) Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives. Neurology and Therapy |
| Cardwell K, Awadia Z, McKenna O, et al. (2023) Physical activity together for MS (PAT-MS): Secondary outcomes of a randomized controlled feasibility trial. Multiple Sclerosis and Related Disorders. 82: 105399 |
| Fakolade A, Awadia Z, Cardwell K, et al. (2023) Physical Activity Together for Multiple Sclerosis (PAT-MS): A randomized controlled feasibility trial of a dyadic behaviour change intervention. Contemporary Clinical Trials Communications. 36: 101222 |
| Singer BA, Arnold DL, Drulovic J, et al. (2023) Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Multiple Sclerosis (Houndmills, Basingstoke, England). 13524585231205708 |
| Sohaei D, Thebault S, Avery LM, et al. (2023) Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics. 20: 33 |